Case Study Hemophilia

Overall the patient had excellent homecare and was a Calculus Level One. There weren’t any risk factors discussed with this patient, but her concern about the throbbing in her upper jaw was addressed. Her general goal of the appointment was to keep her plaque score the same or lower since she was at 14%. She was a Periodontal Case Type Two based on the bleeding from probing, bone loss, and previous radiographs. The patient said she has been flossing more and is really trying to maintain her plaque score.

The patient has a four unit bridge on her upper anteriors, she has ten missing teeth

According to the National Hemophilia Foundation (n.d.), von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. The condition is named after Finnish physician Erik von Willebrand, who first described it in the 1920s (National Hemophilia Foundation, n.d.). The seriousness of the bleeding varied between family

Hemophilia A is an X-linked disorder caused by a deficient or defective clotting factor VIII (FVIII) protein, and characterized by spontaneous or traumatic bleeding into joints and muscles [Ragni]. It causes afflicted individuals to not be able to coagulate their blood very efficiently or at all when getting an injury in which blood is exposed either internally or externally. This disease can be very dangerous and fatal because major blood loss can occur if the patient has not received treatment.

Hemophilia A is a known X-linked recessive disorder. This condition or bleeding disorder is characterized by a deficiency in the activity of a coagulation factor, which in this case is F8 or coagulation factor VIII. This condition is clinically known to be heterogeneous and its severity depends on the plasma level of the coagulation factor VIII. Varying levels of hemophilia exist which are categorized based on percentage of coagulation factor within blood plasma compared to normal levels.

Her dental restoration consisted of treating 11 caries and 1 extraction. At the conclusion of the dental restoration anesthesia gases were stopped. The patient’s consciousness returned quickly. She remained calm and was extubated. She was transfer to the recovery area and later discharged to the care of her grandfather. Her total anesthesia time was approximately 1.25 hours. Her anesthesia course was uneventful.

“Hemophilia (heem-o-FILL-ee-ah) is a rare bleeding disorder in which the blood doesn 't clot normally.” (NIH, 2013) Hemophilia is a chromosome – linked bleeding disorder caused by

Hemophilia is the most common X-linked inherited bleeding disorder caused by deficiency of coagulation factors VIII (Hemophilia A) and IX (Hemophilia B) [1]. Hemophilia A has a frequency of 1 in 5000 male births, while hemophilia B has a frequency of 1 in 30,000 male births [2]. The severity of the bleeding in hemophilia depends on the level of clotting factor activity [3].

Hemophilia is the oldest known hereditary bleeding disorder. There are two types of hemophilia, A and B (Christmas Disease). Low levels or complete absence of a blood protein essential for clotting causes both. Patients with hemophilia A lack the blood clotting protein, factor VIII, and those with hemophilia B lack factor IX. A person with severe hemophilia has less than 1% of the normal amount of a clotting factor - either Factor VIII (8) or Factor IX (9). People without hemophilia have between 50-150% of the normal level of factor VIII or IX. There are about 20,000 hemophilia patients in the United States. Each year, about 400 babies are born with this disorder. Approximately 85% have hemophilia A and the remainder has hemophilia B.

Hemophilia A and Hemophilia B are inherited bleeding conditions where the blood does not properly coagulate (Center for Disease Control and Prevention 2014)2. The inheritance of hemophilia progresses through a carrying of the gene inflicted and is passed on via mother to child at the time of conception. X and Y chromosomes are distinguished as being the sex hormones of the human body. Hemophilia-A in a sex-linked recessive trait disorder located on the X chromosome and otherwise absent on the Y chromosome. Being that it is located only on the X chromosome, if a son is conceived carrying the gene the disorder will inevitably develop. While in the case of females, for the disease to manifest the carrier for the gene must be on both X chromosomes which is noted to be more. Though most hemophilia diagnosis are associated with males, the chance for the inheritance

Hey do you know what hemophilia is? Well it's a bleeding disorder, when you bleed too much when having an injury making you have too much blood loss. There are treatments that can help you if you have Hemophilia ,but sadly we have no cure for it yet. When you have Hemophilia you have to stay away from things that can hurt you like when you are reading a book you have to be careful because you don't want a paper cut.The treatments that can help you when you have replacement therapy, replacement therapy is a treatment aimed at making up a deficit of a substance normally present in the body.

Hemophilia A, an X-linked genetic disease, is the most common coagulation disorder with an incidence of about 1-2 in 10,000 males and is caused by mutations in the factor VIII (FVIII) coagulation gene [PubMed1]. It causes infected individuals to not be able to coagulate their blood efficiently or at all when getting a cut or some injury in which blood is exposed. This disease can be very deadly because of major blood loss.

Hemophilia describes a group of sever congenital coagulation factor deficiencies. It is a lifelong genetic disorder with a prevalence of 1:10,000 birth and that of the most severe form of the disease to be approximately 6% per 1,00,000 Population (1). Depending on the activity of coagulant factor VIII or IX in blood, hemophilia may be labeled as severe (<1% of normal), moderate (1–4%) or mild (5–25%) (2) . hemophilia is characterized by recurrent haemarthroses inside the less muscular padding joints as knees, elbows and ankles joints (3).

Hemophilia is one of the oldest recognized genetic diseases. The first known cases of hemophilia were recorded 1,500 years ago in the Babylonian Talmud. When the Jewish people of this culture performed circumcision, the infant boys occasionally experienced excessive bleeding and sometimes even fatalities. They documented this in their writings which stated that newborn boys did not have to be circumcised if two of their brothers had previously died because of bleeding from this procedure. This documentation not only shows that this disease existed at that time in history, but it also shows that they recognized the bleeding disease as being hereditary. Much later, in 1803, a Philadelphia physician named John Conrad Otto published an article about a bleeding disorder. His research described a disease that primarily affected men and was only linked to certain families. After Otto’s article in 1828, a student and his professor at the University of Zurich coined the

Occasionally a baby is born with this disorder and no family history of it. When this happens, it could be caused by a hidden gene, which is when several generations of female carry it, and it has not affected any male members of the family or a spontaneous mutation. With each pregnancy, a woman who is a carrier has a 25% possibility of having a son born with hemophilia. Since the father's X chromosome is what determines if the unborn child will be a girl, all of the daughters born of a man with hemophilia will be carriers. None of his sons, which is determined by the father through his Y chromosome, will have hemophilia. Individuals who suffer from mild hemophilia may choose to use a non-blood product known as Desmopressin acetate (DDAVP) to help treat the small bleeds and/or scrapes. For deep cuts or internal bleeding, the treatment called DDAVP may not be enough and therefore, may need a much more complex treatment. The clotting factor must be replenished so the affected person can form a clot to stop the bleeding. Plasma is one of the ‘human blood products’ than is used for factor replacement. Another factor replacement option is using the recombinant factor, which is produced in a laboratory.